Jihui Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jihui Du has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Hekai Zhou
Research Center for Clinical and Translational Medicine, Central Laboratory, Shenzhen Nanshan People's Hospital and the 6th Affiliated Hospital of Shenzhen University Medical School, 89# Taoyuan Road, Nanshan District, Shenzhen, 518052, Guangdong, China
3 shared publicationsHoucong Liu
Research Center for Clinical and Translational Medicine, Central Laboratory, Shenzhen Nanshan People's Hospital and the 6th Affiliated Hospital of Shenzhen University Medical School, 89# Taoyuan Road, Nanshan District, Shenzhen, 518052, Guangdong, China
3 shared publicationsChangpu Song
Guangdong Jiyin Biotech, D3 Building, TCL international E city, no. 1001, Zhong Shan Yuan Road, Nanshan District, Shenzhen, China
2 shared publicationsDan Chen
Guangdong Jiyin Biotech, D3 Building, TCL international E city, no. 1001, Zhong Shan Yuan Road, Nanshan District, Shenzhen, China
2 shared publicationsHaijiu Lin
Guangdong Jiyin Biotech, D3 Building, TCL international E city, no. 1001, Zhong Shan Yuan Road, Nanshan District, Shenzhen, China
2 shared publicationsLoren Hansen
El Capitan Biosciences, 7068 Koll Center Pkwy, Suite 402, Pleasanton, CA, 94566, USA
2 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1809451
A pilot study of nebulized 3D-cultured mesenchymal stem cell-derived extracellular vesicles for the treatment of post-COVID-19 chronic cough
Introduction: Chronic cough, particularly prevalent in post-COVID condition (PCC, also known as long COVID), remains a significant medical challenge. Recently, extracellular vesicles (EVs) have gained significant attention for their therapeutic potential. Methods: In this study, we explore the therapeutic effects of EVs derived from mesenchymal stem cells (MSCs) cultured in a 3D system (3D-EVs) in treating chronic cough, with a focus on post-COVID-19 patients. Results: Our in vitro experiments demonstrated that 3D-EVs promote angiogenesis and cell migration, crucial processes in tissue repair and regeneration. Notably, 3D-EVs exhibited a robust suppressive effect on lymphocyte proliferation in human PBMCs, indicating their potential immunomodulatory role. At day 6, nebulized 3D-EVs treatment group showed significantly higher rates of significant improvement (22.5% vs. 5.0%, P = 0.023) and total effectiveness (67.5% vs. 47.5%, P = 0.035), as well as a shorter mean time to cough resolution (13.83 vs. 19.90 days, P = 0.037). By day 14, total effective rates were comparable (85% vs. 80%, P > 0.05). No safety concerns were observed. RNA sequencing revealed altered B cell receptor signaling and downregulation of the mitotic cell cycle pathway, while exploratory immunophenotyping identified a significant reduction in plasma cells ( P < 0.05) and directional trends in other immune subsets, providing preliminary evidence that 3D-EVs may modulate B cell differentiation and immune responses. Conclusion: These findings demonstrate the feasibility and preliminary efficacy of 3D-EVs for rapid relief of post-COVID-19 chronic cough, supporting larger controlled trials to validate their role in this and related respiratory diseases.
- 21 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1809451
Open AccessA pilot study of nebulized 3D-cultured mesenchymal stem cell-derived extracellular vesicles for the treatment of post-COVID-19 chronic cough
Introduction: Chronic cough, particularly prevalent in post-COVID condition (PCC, also known as long COVID), remains a significant medical challenge. Recently, extracellular vesicles (EVs) have gained significant attention for their therapeutic potential. Methods: In this study, we explore the therapeutic effects of EVs derived from mesenchymal stem cells (MSCs) cultured in a 3D system (3D-EVs) in treating chronic cough, with a focus on post-COVID-19 patients. Results: Our in vitro experiments demonstrated that 3D-EVs promote angiogenesis and cell migration, crucial processes in tissue repair and regeneration. Notably, 3D-EVs exhibited a robust suppressive effect on lymphocyte proliferation in human PBMCs, indicating their potential immunomodulatory role. At day 6, nebulized 3D-EVs treatment group showed significantly higher rates of significant improvement (22.5% vs. 5.0%, P = 0.023) and total effectiveness (67.5% vs. 47.5%, P = 0.035), as well as a shorter mean time to cough resolution (13.83 vs. 19.90 days, P = 0.037). By day 14, total effective rates were comparable (85% vs. 80%, P > 0.05). No safety concerns were observed. RNA sequencing revealed altered B cell receptor signaling and downregulation of the mitotic cell cycle pathway, while exploratory immunophenotyping identified a significant reduction in plasma cells ( P < 0.05) and directional trends in other immune subsets, providing preliminary evidence that 3D-EVs may modulate B cell differentiation and immune responses. Conclusion: These findings demonstrate the feasibility and preliminary efficacy of 3D-EVs for rapid relief of post-COVID-19 chronic cough, supporting larger controlled trials to validate their role in this and related respiratory diseases.
- 2 December 2025
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (2) , 941-962
FGF2 Enhances MSCs Secretome Therapy for Skin Photoaging by Delaying Senescence via iNAMPT/AMPK Signaling and Facilitating eNAMPT-Mediated Regenerative Crosstalk
- 2 December 2025
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (2) , 941-962
FGF2 Enhances MSCs Secretome Therapy for Skin Photoaging by Delaying Senescence via iNAMPT/AMPK Signaling and Facilitating eNAMPT-Mediated Regenerative Crosstalk
- Open Access
- 11 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 29397
Bioinformatic screen with clinical validation for the identification of novel stool based mRNA biomarkers for the detection of colorectal lesions including advanced adenoma
Messenger RNA (mRNA) stool based biomarkers represent a promising approach for the diagnosis of colorectal cancer (CRC) and advanced adenoma (AA). But it is unclear which mRNA biomarkers have the most clinical utility. This study aims to partially fill this gap by performing an analysis which first ranks genes based on their expression profile in publicly available RNA-seq tissue datasets. Each gene was ranked based on observed differential expression across the majority of tumors as well as the level of expression in tumor tissue. Those genes with strong differential expression across the majority of tumors that were also highly expressed would have a higher ranking. The top 20 genes as ranked in the bioinformatic analysis of tumor and normal colon tissue gene expression were then tested on 114 clinical stool samples (CRC N = 33, AA N = 28, Controls N = 53). Fourteen of the genes had significant differential expression in the stool of CRC patients compared to controls (false discovery rate or FDR < 0.05). The Pearson correlation coefficient between tissue and stool expression was 0.57 (p-value = 0.007). The combined performance of the 20 genes in clinical stool samples had an area under the receiver operator curve (AUC) of 0.94 for CRC detection (sensitivity 75.5%, specificity 95%) and an AUC of 0.83 (sensitivity 55.8%, specificity 92.6%) for AA detection. The ability to use existing public transcriptomic datasets to identify promising candidate genes can substantially reduce the cost and effort required to screen for clinically useful mRNA biomarkers.
- 11 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 29397
Open AccessBioinformatic screen with clinical validation for the identification of novel stool based mRNA biomarkers for the detection of colorectal lesions including advanced adenoma
Messenger RNA (mRNA) stool based biomarkers represent a promising approach for the diagnosis of colorectal cancer (CRC) and advanced adenoma (AA). But it is unclear which mRNA biomarkers have the most clinical utility. This study aims to partially fill this gap by performing an analysis which first ranks genes based on their expression profile in publicly available RNA-seq tissue datasets. Each gene was ranked based on observed differential expression across the majority of tumors as well as the level of expression in tumor tissue. Those genes with strong differential expression across the majority of tumors that were also highly expressed would have a higher ranking. The top 20 genes as ranked in the bioinformatic analysis of tumor and normal colon tissue gene expression were then tested on 114 clinical stool samples (CRC N = 33, AA N = 28, Controls N = 53). Fourteen of the genes had significant differential expression in the stool of CRC patients compared to controls (false discovery rate or FDR < 0.05). The Pearson correlation coefficient between tissue and stool expression was 0.57 (p-value = 0.007). The combined performance of the 20 genes in clinical stool samples had an area under the receiver operator curve (AUC) of 0.94 for CRC detection (sensitivity 75.5%, specificity 95%) and an AUC of 0.83 (sensitivity 55.8%, specificity 92.6%) for AA detection. The ability to use existing public transcriptomic datasets to identify promising candidate genes can substantially reduce the cost and effort required to screen for clinically useful mRNA biomarkers.
- Open Access
Bioinformatic Screen with Clinical Validation for the Identification of Novel Stool Based mRNA Biomarkers for the Detection of Colorectal Lesions Including Advanced Precancerous Lesions
Messenger RNA (mRNA) stool based biomarkers represent a promising approach for the diagnosis of colorectal cancer (CRC) and advanced precancerous lesions (AA). But it is unclear which mRNA biomarkers have the most clinical utility. This study aims to partially fill this gap by performing an analysis which first ranks genes based on their expression profile in RNA-seq tissue datasets. The diagnostic performance of the top 20 ranked genes was then tested using 113 clinical samples (CRC N=33, AA N=28, Controls N=53). Fourteen of the genes had significant differential expression in the stool of CRC patients compared to controls (false discovery rate or FDR < 0.05). The Pearson correlation coefficient between tissue and stool expression was 0.57 (p-value = 0.007). The combined performance of the 20 genes in clinical stool samples had an area under the receiver operator curve (AUC) of 0.94 for CRC detection (sensitivity 75.5%, specificity 95%) and an AUC of 0.83 (sensitivity 55.8%, specificity 92.6%) for AA detection. The ability to use existing public transcriptomic datasets to identify promising candidate genes can substantially reduce the cost and effort required to screen for clinically useful mRNA biomarkers.
Open AccessBioinformatic Screen with Clinical Validation for the Identification of Novel Stool Based mRNA Biomarkers for the Detection of Colorectal Lesions Including Advanced Precancerous Lesions
Messenger RNA (mRNA) stool based biomarkers represent a promising approach for the diagnosis of colorectal cancer (CRC) and advanced precancerous lesions (AA). But it is unclear which mRNA biomarkers have the most clinical utility. This study aims to partially fill this gap by performing an analysis which first ranks genes based on their expression profile in RNA-seq tissue datasets. The diagnostic performance of the top 20 ranked genes was then tested using 113 clinical samples (CRC N=33, AA N=28, Controls N=53). Fourteen of the genes had significant differential expression in the stool of CRC patients compared to controls (false discovery rate or FDR < 0.05). The Pearson correlation coefficient between tissue and stool expression was 0.57 (p-value = 0.007). The combined performance of the 20 genes in clinical stool samples had an area under the receiver operator curve (AUC) of 0.94 for CRC detection (sensitivity 75.5%, specificity 95%) and an AUC of 0.83 (sensitivity 55.8%, specificity 92.6%) for AA detection. The ability to use existing public transcriptomic datasets to identify promising candidate genes can substantially reduce the cost and effort required to screen for clinically useful mRNA biomarkers.
- Open Access
- 12 June 2023
- Published by Springer Nature in Genes & Genomics
- Vol. 45 (8) , 1037-1046
Postoperative circulating tumor DNA detection and CBLB mutations are prognostic biomarkers for gastric cancer
Background: Several studies have demonstrated that circulating tumor DNA (ctDNA) can be used to predict the postoperative recurrence of several cancers. However, there are few studies on the use of ctDNA as a prognosis tool for gastric cancer (GC) patients. Objective: This study aims to determine whether ctDNA could be used as a prognostic biomarker in GC patients through multigene-panel sequencing. Methods: Using next-generation sequencing (NGS) Multigene Panels, the mutational signatures associated with the prognosis of GC patients were identified. We calculated the survival probability with Kaplan–Meier and used the Log-rank test to compare survival curves between ctDNA-positive and ctDNA-negative groups. Potential application of radiology combined with tumor plasma biomarker analysis of ctDNA in GC patients was carried out. Results: Disease progression is more likely in ctDNA-positive patients as characterized clinically by a generally higher T stage and a poorer therapeutic response (P < 0.05). ctDNA-positive patients also had worse overall-survival (OS: P = 0.203) and progression-free survival (PFS: P = 0.037). The combined analysis of ctDNA, radiological, and serum biomarkers in four patients indicated that ctDNA monitoring can be a good complement to radiological and plasma tumor markers for GC patients. Kaplan–Meier analysis using a cohort of GC patients in the TCGA database showed that patients with CBLB mutations had shorter OS and PFS than wild-type patients (OS: P = 0.0036; PFS: P = 0.0027). Conclusions: This study confirmed the utility and feasibility of ctDNA in the prognosis monitoring of gastric cancer.
- 12 June 2023
- Published by Springer Nature in Genes & Genomics
- Vol. 45 (8) , 1037-1046
Open AccessPostoperative circulating tumor DNA detection and CBLB mutations are prognostic biomarkers for gastric cancer
Background: Several studies have demonstrated that circulating tumor DNA (ctDNA) can be used to predict the postoperative recurrence of several cancers. However, there are few studies on the use of ctDNA as a prognosis tool for gastric cancer (GC) patients. Objective: This study aims to determine whether ctDNA could be used as a prognostic biomarker in GC patients through multigene-panel sequencing. Methods: Using next-generation sequencing (NGS) Multigene Panels, the mutational signatures associated with the prognosis of GC patients were identified. We calculated the survival probability with Kaplan–Meier and used the Log-rank test to compare survival curves between ctDNA-positive and ctDNA-negative groups. Potential application of radiology combined with tumor plasma biomarker analysis of ctDNA in GC patients was carried out. Results: Disease progression is more likely in ctDNA-positive patients as characterized clinically by a generally higher T stage and a poorer therapeutic response (P < 0.05). ctDNA-positive patients also had worse overall-survival (OS: P = 0.203) and progression-free survival (PFS: P = 0.037). The combined analysis of ctDNA, radiological, and serum biomarkers in four patients indicated that ctDNA monitoring can be a good complement to radiological and plasma tumor markers for GC patients. Kaplan–Meier analysis using a cohort of GC patients in the TCGA database showed that patients with CBLB mutations had shorter OS and PFS than wild-type patients (OS: P = 0.0036; PFS: P = 0.0027). Conclusions: This study confirmed the utility and feasibility of ctDNA in the prognosis monitoring of gastric cancer.
- Open Access
- 5 November 2020
- Published by Springer Nature in Research Square
MiRNA-92a Promote Angiogenesis in Colorectal Cancer by Inhibiting the Expression of PTEN
Background: The microRNA (miRNA) miRNA-92a has been implicated in colorectal cancer (CRC) pathology. Methods: Here, we examined miRNA-92a involvement in CRC-associated angiogenesis, including examining a mechanism by which miRNA-92a may exert such effects. MiRNA-92a expression in 25 clinical CRC samples and in HT29, SW620, SW480 and HCT116 CRC cells was detected with quantitative real-time polymerase chain reaction (qRT-PCR). Blood microvessels were labeled by immunohistochemistry (IHC) with an anti-CD31 antibody. MiR-92a mimic or inhibitor were transfected into HCT116 and SW620 cells to up- and down-regulate miRNA-92a expression, respectively. The effects of altering miRNA-92a expression levels on HUVEC (human umbilical vein endothelial cell) tubule formation and PTEN protein expression were measured. Results: MiRNA-92a was more highly expressed in CRC tissues and cell lines than in matched adjacent tissues (p p p r = 0.580, p = 0.01). The cells culture supernatant of CRC cell with miRNA-92a overexpression (or suppression) can promoted (or reduced) the formation of HUVEC tubules (P p Conclusion: Modulation of miR-92a, which is highly expressed in CRC cells and tissues, is associated directly with differences in CRC angiogenesis. MiR-92a could promote tumor angiogenesis in CRC by inhibiting the expression of PTEN.
- 5 November 2020
- Published by Springer Nature in Research Square
Open AccessMiRNA-92a Promote Angiogenesis in Colorectal Cancer by Inhibiting the Expression of PTEN
Background: The microRNA (miRNA) miRNA-92a has been implicated in colorectal cancer (CRC) pathology. Methods: Here, we examined miRNA-92a involvement in CRC-associated angiogenesis, including examining a mechanism by which miRNA-92a may exert such effects. MiRNA-92a expression in 25 clinical CRC samples and in HT29, SW620, SW480 and HCT116 CRC cells was detected with quantitative real-time polymerase chain reaction (qRT-PCR). Blood microvessels were labeled by immunohistochemistry (IHC) with an anti-CD31 antibody. MiR-92a mimic or inhibitor were transfected into HCT116 and SW620 cells to up- and down-regulate miRNA-92a expression, respectively. The effects of altering miRNA-92a expression levels on HUVEC (human umbilical vein endothelial cell) tubule formation and PTEN protein expression were measured. Results: MiRNA-92a was more highly expressed in CRC tissues and cell lines than in matched adjacent tissues (p p p r = 0.580, p = 0.01). The cells culture supernatant of CRC cell with miRNA-92a overexpression (or suppression) can promoted (or reduced) the formation of HUVEC tubules (P p Conclusion: Modulation of miR-92a, which is highly expressed in CRC cells and tissues, is associated directly with differences in CRC angiogenesis. MiR-92a could promote tumor angiogenesis in CRC by inhibiting the expression of PTEN.
- 20 November 2013
- Published by Wiley in The Journal of Pathology
- Vol. 232 (3) , 356-368
Epidermal overexpression of transgenic ΔNp63 promotes type 2 immune and myeloid inflammatory responses and hyperplasia via NF‐κB activation
ΔNp63 is known to be critical in skin development and cancer; however, how it triggers proliferation and inflammation in vivo remains to be elucidated. Here, we find that induced ΔNp63 expression in skin of transgenic mice (TG) results in a hyperproliferative epidermis coupled with inflammatory infiltrates. In situ, infiltrating cells include CD45+ leukocytes, CD19+ B lymphocytes, CD3+ T lymphocytes, CD4+ T helper, CD25+/Foxp3+ Treg, Ly6B+ neutrophils, S‐100+ dendritic cells, and macrophages bearing CD11b+, F4/80+, CD68+, and CD206+ M2 type markers. Transcriptional profiling of TG skin revealed increased gene expression involved in inflammation and immune responses, including Th2/M2 cytokines and chemokines. These genes were co‐regulated by ΔNp63 and NF‐κB RelA or cRel, and enhanced by TNF‐α. Elevated cRel, RelA, and IKKs were observed in TG mouse skin and human squamous carcinomas with ΔNp63 overexpression. Thus, our findings unveil a missing link connecting overexpressed ΔNp63 with aberrant NF‐κB activation, pro‐inflammatory and type 2 cytokines and chemokines, and host infiltrates during skin inflammation and hyperplasia. Our findings provide a missing link between ΔNp63 overexpression and NF‐κB‐mediated inflammation, of potential relevance to the pathogenesis of squamous carcinoma. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
- 20 November 2013
- Published by Wiley in The Journal of Pathology
- Vol. 232 (3) , 356-368
Epidermal overexpression of transgenic ΔNp63 promotes type 2 immune and myeloid inflammatory responses and hyperplasia via NF‐κB activation
ΔNp63 is known to be critical in skin development and cancer; however, how it triggers proliferation and inflammation in vivo remains to be elucidated. Here, we find that induced ΔNp63 expression in skin of transgenic mice (TG) results in a hyperproliferative epidermis coupled with inflammatory infiltrates. In situ, infiltrating cells include CD45+ leukocytes, CD19+ B lymphocytes, CD3+ T lymphocytes, CD4+ T helper, CD25+/Foxp3+ Treg, Ly6B+ neutrophils, S‐100+ dendritic cells, and macrophages bearing CD11b+, F4/80+, CD68+, and CD206+ M2 type markers. Transcriptional profiling of TG skin revealed increased gene expression involved in inflammation and immune responses, including Th2/M2 cytokines and chemokines. These genes were co‐regulated by ΔNp63 and NF‐κB RelA or cRel, and enhanced by TNF‐α. Elevated cRel, RelA, and IKKs were observed in TG mouse skin and human squamous carcinomas with ΔNp63 overexpression. Thus, our findings unveil a missing link connecting overexpressed ΔNp63 with aberrant NF‐κB activation, pro‐inflammatory and type 2 cytokines and chemokines, and host infiltrates during skin inflammation and hyperplasia. Our findings provide a missing link between ΔNp63 overexpression and NF‐κB‐mediated inflammation, of potential relevance to the pathogenesis of squamous carcinoma. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.